Roche-HIV.com - HIV therapy adherence

HIV Therapy Adherence

HIV Adherence Studies
Definitions of adherence in HIV studies have generally used a cut-off of more than 80% of the prescribed doses taken over the period being investigated^14-17. Studies of zidovudine therapy have reported adherence rates of 60-88%^14-17. However, in a study of attitudes and beliefs towards zidovudine therapy, adherence was estimated to be only 42%¹⁸. This level of adherence is consistent with studies in other chronic illnesses.

In HIV infected people taking zidovudine, factors that have been found to influence adherence include^19,20:

substance abuse
drug toxicity
complexity and frequency of doses
education about treatment expectations of drug efficacy
individual’s perceptions about severity of HIV disease
ethnicity
social and economic circumstances

In one study, people taking more than 3 times daily dosing, or an average of more than 4.5 medications, were significantly less adherent than those on twice daily regimens and fewer medications. Knowledge about medication was associated with improved adherence¹⁷.

People with HIV may be symptom free in the early stages of the disease, so the results of non-adherence may not be evident until much later²¹. Non-adherence is more common among people with psychological distress, depression and poor adaptive and coping mechanisms. People with HIV who have had opportunistic infections are more likely to adhere to therapy²⁰. Taken together, these findings underline the challenges of starting complex multi-drug regimens for people with asymptomatic disease who may still be coming to terms with their HIV positivity.

Adherence to Antiretroviral Combination Therapy